Study guide

2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

Certified Genetic Counselor CGC

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 About the CGC Exam & Credential 1.2 Eligibility Categories, Application & Fees 1.3 Scoring, Pass Rate & Test-Day Logistics

2 Domain 1A: Clinical Information

1.4 Medical & Pregnancy History 1.5 Teratogens, Exposures & Non-Genetic Risk Factors 1.6 Differential Diagnosis, Indication & Referral Urgency 1.7 Referral Triage, Case Preparation & Records Review

3 Domain 1B: Human Development

1.8 Fetal Development 1.9 Developmental Milestones 1.10 Physical & Psychological Development

4 Domain 1C: Chromosomal & Contiguous Gene Syndromes

1.11 Aneuploidy Syndromes (Down, Turner, Klinefelter, Edwards, Patau) 1.12 Microdeletion Syndromes (22q11.2, Williams, and Related) 1.13 Imprinting Disorders (PWS, Angelman, Beckwith-Wiedemann, Russell-Silver)

5 Domain 1C: Hereditary Cancer Syndromes

1.14 Hereditary Breast & Ovarian Cancer (BRCA1/2, PALB2, and Related) 1.15 Lynch Syndrome & Polyposis Syndromes 1.16 Li-Fraumeni, VHL, MEN, NF1/NF2 & Other Cancer Predisposition

6 Domain 1C: Metabolic, Neuromuscular & Multisystem Conditions

1.17 Inborn Errors of Metabolism & Storage Disorders 1.18 Neuromuscular Disease & Fragile X Spectrum 1.19 Connective Tissue & Cardiovascular Genetics 1.20 Screening, Surveillance, Treatment & Diagnostic Strategy Framework

7 Domain 2A: Pedigree & Risk Assessment

2.1 Family History, Pedigree Construction & Analysis 2.2 Mendelian Risk Calculations 2.3 Bayesian Risk Calculations 2.4 Empiric Risk, Multifactorial Recurrence & Risk-Assessment Models 2.5 Residual Risk & Follow-Up Medical Plans

8 Domain 2B: Inheritance Principles

2.6 Mendelian Inheritance Patterns 2.7 Non-Mendelian Inheritance (Mitochondrial, Imprinting, Multifactorial) 2.8 Penetrance, Expressivity, Anticipation & Heterogeneity 2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

9 Domain 2B: Population Genetics & Variation

2.10 Population Genetics, HWE & Quantitative Genetics 2.11 Human Genetic Variation & Disease Susceptibility

10 Domain 3A: Test Methodologies

3.1 Karyotype, FISH & Chromosomal Microarray 3.2 Molecular Diagnostics (Sanger, NGS Panels, WES, WGS, MLPA) 3.3 Sample Types, Clinical Context & Predictive Metrics

11 Domain 3A: Variant Interpretation

3.4 ACMG/AMP Variant Classification 3.5 Reanalysis, Reclassification & Validity/Utility Framework

12 Domain 3B: Testing Options

3.6 Diagnostic Testing Strategies 3.7 Screening Testing (including Newborn Screening) 3.8 Predictive & Pre-symptomatic Testing 3.9 Carrier, Somatic & Research Testing

13 Domain 3C: Reproductive Risk Management

3.10 Assisted Reproductive Technologies & PGT 3.11 Family Planning & Reproductive Options 3.12 Prenatal Screening (NIPT, Serum Markers) 3.13 Prenatal Diagnostic Procedures (CVS, Amniocentesis)

14 Domain 4A: Counseling Foundations

4.1 Contracting & Interviewing Techniques 4.2 Psychosocial Assessment, Follow-Up & Family Dynamics 4.3 Client Personal Identity & Cultural Humility

15 Domain 4A: Theories, Coping & Dynamics

4.4 Counseling Theories & Models (REM, Trajectory) 4.5 Defense Mechanisms, Coping & Decision-Making Styles 4.6 Grief, Perinatal Loss & Crisis Response 4.7 Self-Awareness & Client-Counselor Dynamics

16 Domain 4B: Communication & Education

4.8 Delivery Modes & Working with Interpreters 4.9 Risk Communication Theories & Models 4.10 Results Delivery & Long-Term Follow-Up 4.11 Health Literacy, Informed Consent & Informed Decision Making

17 Domain 5A–B: Finance & Client Resources

5.1 Insurance Policies, Billing & Letters of Medical Necessity 5.2 Billing, Coding & Reimbursement Compliance 5.3 Client Resources, Appropriateness & Timely Delivery

18 Domain 5C: Legal & Regulatory Requirements

5.4 GINA & Genetic Non-Discrimination Legislation 5.5 Privacy, Confidentiality, Documentation & Genomic Data Security 5.6 Human-Subjects Research Standards & Patient Access to Information 5.7 CLIA, Laboratory-Developed Tests & FDA Oversight 5.8 Genomic Data Security, DTC Testing & Data Sharing

19 Domain 5D: Professional Frameworks

5.9 NSGC Code of Ethics & Ethical Decision Making 5.10 Scope of Practice, Clinical Supervision & Conflict of Interest 5.11 Licensure, Credentialing & Maintaining the CGC Credential 5.12 Evidence-Based Practice & Professional/Public Education

20 Integration & Exam Strategy

6.1 Integrating Domains in Case-Based Practice & Exam Strategy

2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

Key Takeaways Explain This Topic AI

Mosaicism arises from a post-zygotic event, so the distribution of the variant depends on when in development it occurred — which is why blood can be negative while affected tissue is positive.

Germline (gonadal) mosaicism means an apparently de novo dominant condition carries a small but real recurrence risk; commonly quoted figures reach roughly 10–15% for Duchenne muscular dystrophy and around 6% for lethal osteogenesis imperfecta.

Skewed X-inactivation explains manifesting female carriers of X-linked conditions such as Duchenne muscular dystrophy, Fabry disease, and hemophilia.

Uniparental disomy arises most often through trisomy rescue, which is also why confined placental mosaicism and UPD frequently appear in the same case.

Isodisomy can unmask an autosomal recessive condition when only one parent is a carrier — a scenario that breaks the expected recessive pedigree pattern.

Last updated: August 2026

2.9 Mosaicism, X-Inactivation & Epigenetic Modifiers of Phenotype

Quick Answer: Mosaicism = post-zygotic variant, so timing sets tissue distribution and blood may be falsely negative. Germline mosaicism keeps recurrence above zero after an "apparently de novo" dominant diagnosis. Skewed X-inactivation produces manifesting female carriers. Uniparental disomy usually arises by trisomy rescue , explains PWS/AS/Russell-Silver/Beckwith-Wiedemann subsets, and can unmask a recessive condition from a single carrier parent .

Subdomain 2B carries 15 scored items , and its second listed sub-topic is factors that influence phenotype and genotype . Penetrance, expressivity, anticipation, and heterogeneity are covered earlier in this chapter; this section handles the mechanisms that make a genotype inconsistent across cells or inconsistent with parental origin .

Mosaicism: one person, two or more cell lines

Mosaicism results from a post-zygotic mutational or segregation event. The earlier it occurs, the more tissues are involved.

Type Cells involved Consequence

Somatic Body tissues, not gametes Variable, often segmental phenotype; no transmission risk to offspring from the somatic line

Germline (gonadal) Gametes, not detectable in soma Parent is clinically unaffected and blood-negative, yet can have multiple affected children

Gonosomal (somatic + germline) Both Mildly or segmentally affected parent with transmission risk

Confined placental Trophoblast/placenta, not fetus Discordant CVS or cfDNA results; may associate with IUGR and with UPD

  • Revertant Spontaneous correction in a clone Patches of unaffected tissue in otherwise affected skin conditions
  • Germline mosaicism and the recurrence conversation

This is the highest-yield mosaicism concept on the exam. When a child has an apparently de novo autosomal dominant condition and both parents test negative in blood, recurrence is low but not zero . Commonly quoted teaching figures include roughly 10–15% for Duchenne muscular dystrophy and around 6% for lethal (type II) osteogenesis imperfecta ; many other dominant conditions are counseled at about 1% empirically. The counseling line is that "de novo" describes what was found in the parents' blood, not a guarantee about their gametes — and that prenatal or preimplantation testing remains available for that residual risk.

Detecting mosaicism

Variant allele fraction (VAF) on next-generation sequencing is the practical signal: a heterozygous germline variant sits near 50%, while a mosaic variant may appear at 5–30% or lower.

Read depth matters. Low-depth sequencing and Sanger confirmation both miss low-level mosaicism; the lab may need deep targeted sequencing or droplet digital PCR.

Tissue choice matters. For a segmental skin phenotype, affected skin fibroblasts may be positive when blood is negative. For suspected mosaic aneuploidy, blood plus a second tissue may be needed.

Classic somatic-mosaic disorders exist only in the mosaic state because the constitutional form is lethal: Proteus syndrome ( AKT1 ), McCune-Albright syndrome ( GNAS ), and segmental NF1 are the standard examples.

X-inactivation and manifesting carriers

X-inactivation (lyonization) silences one X chromosome in each somatic cell of a 46,XX individual. It occurs early in embryogenesis, is usually random , and is clonally maintained — so all descendants of a cell keep the same inactive X.

Three consequences drive exam items:

Skewed X-inactivation produces manifesting carriers. If the X carrying the pathogenic variant is preferentially active, a heterozygous female can show symptoms. Classic manifesting-carrier scenarios include Duchenne muscular dystrophy (elevated CK, cardiomyopathy), Fabry disease , X-linked adrenoleukodystrophy , and hemophilia A/B with clinically relevant factor levels. A negative family history plus a symptomatic female does not exclude an X-linked condition.

Some genes escape inactivation. Roughly 15–25% of X-linked genes escape silencing to some degree, mostly in the pseudoautosomal regions and scattered loci. Escape explains why 45,X (Turner syndrome) has a phenotype at all — haploinsufficiency for escape genes such as SHOX — and why supernumerary X material in 47,XXY and 47,XXX is not phenotypically silent.

Discordant monozygotic twins. Female MZ twins can be discordant for an X-linked phenotype because inactivation was skewed differently in each twin — a favorite distractor-buster for "identical twins must be identical."

Uniparental disomy

Uniparental disomy (UPD) is inheritance of both homologues of a chromosome pair from one parent.

Term Meaning Recessive-disease consequence

Heterodisomy Both different homologues from one parent (meiosis I error) Cannot make a carrier parent's heterozygous variant homozygous by itself

Isodisomy Two copies of the same homologue (meiosis II error or post-zygotic duplication) Can unmask a recessive condition carried by only one parent

Mechanisms

Trisomy rescue is the commonest route: a trisomic conceptus loses one chromosome; one-third of the time the retained pair is from a single parent. This is also why confined placental mosaicism and UPD travel together — the trisomic line persists in the placenta while the fetus is disomic.

Monosomy rescue duplicates the single inherited chromosome, producing complete isodisomy.

Gamete complementation and post-zygotic errors account for the remainder.

Imprinted-region UPD you must recognize

  • Chromosome Parental origin Condition
  • 15q11-q13 Maternal UPD15 Prader-Willi syndrome (~25–30% of cases)
  • 15q11-q13 Paternal UPD15 Angelman syndrome (a small minority, ~3–5%)
  • 7 Maternal UPD7 Russell-Silver syndrome (~7–10% of cases)
  • 11p15 Paternal UPD11p Beckwith-Wiedemann syndrome (~20% of cases)
  • 14 Maternal or paternal UPD14 Temple and Kagami-Ogata syndromes

The single-carrier-parent trap. A child has a classic autosomal recessive condition, and testing shows the child is homozygous for a pathogenic variant — but only the father carries it and maternity is confirmed. The correct interpretation is paternal isodisomy for that chromosome, not non-paternity and not a lab error. Recurrence for future siblings is very low, because the event was a sporadic segregation accident rather than two carrier parents.

The epigenetic layer

Imprinting is maintained by DNA methylation at imprinting control regions, so imprinting disorders can arise by four distinct routes: deletion , UPD , imprinting-centre defect , or (for Angelman) a UBE3A sequence variant. This is why methylation-specific testing — methylation-specific MLPA or methylation-specific PCR — is the correct first-tier test for PWS/AS: it detects the abnormal methylation pattern regardless of which of the first three mechanisms produced it, and follow-up testing then distinguishes deletion from UPD from imprinting defect. Sequencing alone will miss all three.

Assisted reproductive technologies have been associated in the literature with a modest increase in imprinting disorders such as Beckwith-Wiedemann; counsel this as an association with small absolute risk rather than as an established causal quantity.

Common traps

Reporting a negative blood test as excluding mosaicism when the phenotype is segmental.

Telling parents of a child with an apparently de novo dominant condition that recurrence is zero .

Concluding non-paternity when a child is homozygous for a variant carried by only one parent, instead of considering isodisomy .

Assuming a symptomatic female excludes X-linked inheritance.

Ordering sequencing alone for suspected Prader-Willi or Angelman syndrome instead of methylation analysis.

Treating heterodisomy and isodisomy as interchangeable when reasoning about recessive unmasking.